HMG-CoA reductase inhibitors or statins are effective in both the primary and secondary
prevention of coronary heart disease, the extent of benefit being proportional to the …

This article reviews the pharmacokinetic properties of HMG-CoA reductase inhibitors (or
statins), as reported in humans. Most data presented here refer to commercially available …

Fluvastatin, the first fully synthetic HMG-CoA reductase inhibitor, has been shown to reduce
cholesterol in patients with hyperlipidaemia, to prevent subsequent coronary events in …

Background Itraconazole, a potent inhibitor of CYP3A4, increases the risk of skeletal muscle
toxicity of some 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors …

The oral bioavailability of two HMG‐CoA reductase inhibitors, pravastatin and lovastatin,
was investigated in this randomized, two‐way crossover study. Twenty healthy men were …

Since simvastatin is metabolised by the cytochrome P450 system, a potential for drug
interactions exists. Elevated HMG-CoA reductase inhibitory activity has been observed …

Synopsis Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts
by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) …

Statins are the treatment of choice for the management of hypercholesterolaemia because of
their proven efficacy and safety profile. They also have an increasing role in managing …

Abstract This 6-week, double-blind clinical trial evaluated lipid parameter responses to
different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin …

Plasma cholesterol and other lipoproteins play a significant role in the development of
atherosclerosis and subsequent coronary heart disease (CHD). This 1 year study was …